Chen Q, Hetzel F W
Research and Development, HealthONE, Denver, CO 80208, USA.
J Clin Laser Med Surg. 1998 Feb;16(1):9-12. doi: 10.1089/clm.1998.16.9.
To review the currently available data of photodynamic therapy (PDT) optical dosimetry for possible prostatic applications.
PDT is a new cancer treatment modality often used as an alternative tumor treatment method. Recently, PDT has been suggested as an alternative therapy for prostatic carcinoma and BPH.
PDT: utilizes light and a preadministered photosensitizer drug to achieve localized tumor control. This article reviews currently available data on optical dosimetry of PDT in both human and canine prostates.
At 630 nm, a common wavelength used for Photofrin PDT, results indicate that light penetration is similar in cancerous and normal prostatic tissue. Because of limited light penetration, multiple fiber irradiation is necessary if eradicating the entire prostate glad is the ultimate goal. The available data also show that dynamic changes occur in light fluence rate distribution during PDT irradiation.
PDT can be used to destroy prostatic tissue. Real-time optical dosimetry is necessary if accurate lesion volume control is desired.
回顾目前可获得的光动力疗法（PDT）光学剂量测定法在前列腺疾病中可能应用的数据。
PDT是一种新的癌症治疗方式，常被用作替代肿瘤治疗方法。最近，PDT已被提议作为前列腺癌和良性前列腺增生症（BPH）的替代疗法。
PDT利用光和预先给予的光敏剂药物来实现局部肿瘤控制。本文回顾了目前可获得的关于人类和犬类前列腺中PDT光学剂量测定法的数据。
在用于Photofrin PDT的常用波长630 nm处，结果表明光在癌性和正常前列腺组织中的穿透情况相似。由于光穿透有限，如果最终目标是根除整个前列腺腺体，则需要多次光纤照射。现有数据还表明，在PDT照射期间光通量率分布会发生动态变化。
PDT可用于破坏前列腺组织。如果需要精确控制病变体积，则实时光学剂量测定是必要的。
